The collaboration targets disease areas where conventional small molecule drug discovery has faced challenges.

GLP-1 receptor agonists hold key market opportunities due to their effectiveness in diabetes and obesity management, ...

For patients with cancer and brain metastases (BM) and type 2 diabetes (T2D), glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with significantly lower all-cause mortality, ...

Opportunities in the GLP-1 receptor agonist market include the development of new diabetes and obesity treatments with high ...

The use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with reduced risks for developing substance use disorders (SUDs).

The 2026 European Association of Urology (EAU) annual meeting featured an advancing prognostics and therapeutics in ...

Researchers at the University of California San Diego have uncovered how a single protein triggers two opposite responses in blood vessels—one inflammatory and one protective. This protein, a ...

Taking GLP-1 RAs is associated with fewer hospitalizations overall and less need for medications used to stop and prevent ...

Advancing the Discovery of Novel Therapies and Building an Integrated Drug Discovery Platform by Combining PPI Science with AI - ...

Researchers at the University of California San Diego have uncovered how a single protein triggers two opposite responses in blood vessels - one inflammatory and one protective. This protein, a ...